PEMBROKE, MA, September 09, 2025 /24-7PressRelease/ -- Alex Lagadinos has been selected for inclusion in Marquis Who's Who. As in all Marquis Who's Who biographical volumes, individuals profiled are selected on the basis of current reference value. Factors such as position, noteworthy accomplishments, visibility, and prominence in a field are all taken into account during the selection process.

Dr. Lagadinos has established himself as an expert in biotech business development and strategy, currently serving as the Head of Business Development at Mana.bio, an artificial-intelligence-based drug delivery startup, since 2024. In this capacity, his role is focused primarily on sell-side business development and strategy - shaping key corporate initiatives, identifying strategic partners, negotiating transactions, and managing alliances after agreements are signed.

A daily routine shaped by Mana.bio's headquarters in Tel Aviv, Israel, Dr. Lagadinos uses his early mornings to collaborate with Israeli colleagues, and his afternoons to work with local partners. Throughout his workday, Dr. Lagadinos leads an array of partnerships across all stages of negotiation, analyzes data and prepares due diligence materials, and represents the company's key achievements at conferences and board meetings. The dynamic nature of his responsibilities aligns with Dr. Lagadinos's preference for intellectually diverse environments that demand both analytical depth, mindful negotiation, and strategic execution.

Dr. Lagadinos was drawn to Mana.bio by its innovative approach to drug delivery and its inspirational leadership team. The company is pioneering the use of machine learning to predict properties of lipid nanoparticles, which can be used to deliver a broad array of genetic medicines. He recognized the transformative potential of combining artificial intelligence (AI) with empirical data to effectively learn from every single experiment. At Mana.bio, every data point is captured and analyzed by AI tools, enabling real-time insights and accelerating scientific progress. Dr. Lagadinos values the company's commitment to integrity, innovation, and intellectual rigor, finding the work both demanding and deeply rewarding.

With over a decade of career history in this sector, Dr. Lagadinos previously served as the Senior Director of Corporate Development at ReNAgade Therapeutics in Cambridge, Massachusetts, from 2022 to 2024. This role also focused largely on business development and strategy, where Dr. Lagadinos managed technology in-licenses and strategic out-licenses, which ultimately culminated in a substantial deal with Vertex Pharmaceuticals after ReNAgade was acquired by its sister company, Orna Therapeutics in 2024. He also served as the Director of Corporate Business Development at National Resilience in Cambridge between 2021 and 2022, where his role was focused on the development of innovative bioprocessing technologies and financing companies that could also leverage Resilience's bio-manufacturing services as partnership capital.

Earlier, Dr. Lagadinos held a tenure at Sarepta Therapeutics in Cambridge, spanning several positions from 2015 to 2021, where he progressed from a Business Development Intern to Director of Business Development and Strategic Alliances. During this period, he achieved a career-defining milestone by leading the identification and in-licensing of a revolutionary gene therapy for the treatment of Duchenne muscular dystrophy. At a time when no approved disease-modifying therapies existed for Duchenne patients, Dr. Lagadinos spearheaded the diligence process and built the strategic case for investing in an emerging gene therapy program being developed at Nationwide Children's Hospital in Columbus, Ohio. His efforts resulted in Sarepta licensing the program and developing it into Elevidys, one of the only approved gene therapies on the market and a transformative medicine for boys living with Duchenne muscular dystrophy. This breakthrough has become the most successful product of its kind on the market.

His experience in the field of genetic medicines has also afforded Dr. Lagadinos the opportunity to independently consult for companies seeking advice or support on business development activities. While employed by Sarepta Therapeutics, Dr. Lagadinos also served as Scientific Advisor for Patient Identification Platform (Patient I.P.) in Rochester, New York, contributing his expertise in biotechnology strategy from 2015 to 2019. This work and other similar projects led Dr. Lagadinos to form Onyx Ovum LLC in 2024. His independent firm focused on biotech/pharma consulting services. Onyx Ovum refers to the "Black Egg," an ancient symbol used to represent the search for truth or higher purpose.

Dr. Lagadinos's academic background include a Bachelor of Science in Biotechnology from Worcester Polytechnic Institute in 2005, a Doctor of Philosophy in Virology from the University of Massachusetts in 2013, followed by a Postdoctoral Professional Master's degree in Bioscience Management from Keck Graduate Institute in Claremont, California, in 2015, a program designed specifically for post-doctoral professionals seeking non-research roles across various biotech and pharma disciplines.

As an active member of the American Society of Gene and Cell Therapy, Dr. Lagadinos remains engaged with advancements within his field while mentoring colleagues on career development through resume building, job search strategies and professional networking. Civically minded, he has also been involved in events that support patients with terminal cancers and their families and has made financial contributions to various foundations and charitable organizations throughout his career.

Looking ahead, Dr. Lagadinos aims to move deeper into company creation and venture financing, supporting scientific discovery and technological development at their earliest stages by helping form or fund startups where capital investment and strategic direction are critical.

About Marquis Who's Who®:
Since 1899, when A. N. Marquis printed the First Edition of Who's Who in America®, Marquis Who's Who® has chronicled the lives of the most accomplished individuals and innovators from every significant field of endeavor, including politics, business, medicine, law, education, art, religion and entertainment. Who's Who in America® remains an essential biographical source for thousands of researchers, journalists, librarians and executive search firms around the world. The suite of Marquis® publications can be viewed at the official Marquis Who's Who® website, www.marquiswhoswho.com.

# # #